What we can do. What we cannot. Conservative by default.

Two tracks. No ambiguity.

Medical cannabis marketing is heavily restricted in Ireland. The strict two-track approach below ensures every output is defensible. Cite ASAI 7th ed and the Medicinal Products Control of Advertising Regs once on the strategy slide. Verify every clinical or device claim before publishing.

Permitted

Educational unbranded content about MCAP and the conditions it treats
HCP-targeted promotion to registered prescribers (gated content)
Branded promotion of OleoCare app as a digital health platform
Branded promotion of Panacea device, conditional on MDR Class IIa confirmation
Earned media and contributed editorial in trade press
Patient advocacy partnerships (unbranded education)
Organic SEO and AI citation work on educational content
Press / founder profile coverage
Conference speaking and KOL placement (HCP audience)

Not permitted

Public-facing advertising of prescription cannabis products
Performance ads (Google, Meta, TikTok) with product imagery
Off-label clinical claims
Named clinician endorsements without consent
Patient solicitation outside MCAP-approved indications
Social media product mentions (HPRA silence rule)
Discount or promo offers on prescription product
Implied disease-treatment claims without regulatory basis
Patient testimonials without consent and clinician verification

Frameworks referenced.

Framework	Scope	Implication for Oleo
ASAI Code 7th ed	All advertising in Ireland	Section 7 governs medicinal product advertising. Public-facing prescription product advertising is restricted.
Medicinal Products (Control of Advertising) Regulations	Statutory backing for ASAI	Defines "advertising" broadly. Includes social media mentions of named products.
HPRA guidance	Pharmaceutical regulator	Authorises the supplier. Owns the MCAP register. Yellow card scheme for adverse events.
Misuse of Drugs Regulations 1988 / 2017	Controlled drug status	Cannabis Schedule 1 outside MCAP. Per-shipment import licences required.
MDR (EU) 2017/745	Medical device classification	Determines what can be claimed about Panacea device. Class IIa or higher unlocks marketing claims.
GDPR + Data Protection Act 2018	Patient data	OleoCare = Article 9 special-category data. DPIA mandatory before any AI module touches patient information.
HPRA pharmacovigilance	Adverse event reporting	Yellow card scheme. Patient-facing content must direct adverse events to HPRA, not Oleo.